AKT1 and Familial prostate cancer: This finding, coupled with the result that ERG S96A cannot promote tumor formation even in the presence of activated AKT, indicates that the best therapeutic strategy for targeting ERG function in prostate cancer is to inhibit its transcriptional activation function.